Attached files

file filename
10-K/A - 2010 ANNUAL REPORT - AMENDMENT NO. 1 - Boston Therapeutics, Inc.bti_2010-10ka.htm
EX-32.2 - CFO CERTIFICATION - Boston Therapeutics, Inc.bti_exhibit32-2.htm
EX-31.2 - CFO CERTIFICATION - Boston Therapeutics, Inc.bti_exhibit31-2.htm
EX-31.1 - CEO CERTIFICATION - Boston Therapeutics, Inc.bti_exhibit31-1.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of Boston Therapeutics, Inc. (the “Company”) for the year ending December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), David Platt, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

(1) The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Dated:  March 31, 2011 By:  

/s/ David Platt

 

 

 

David Platt

  Chief Executive Officer

 

 This certification accompanies each Report pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by §906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.